Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [31] Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
    Zhang, Jing
    Mattison, Hayley A.
    Liu, Changqin
    Ginghina, Carmen
    Auinger, Peggy
    McDermott, Michael P.
    Stewart, Tessandra
    Kang, Un Jung
    Cain, Kevin C.
    Shi, Min
    ACTA NEUROPATHOLOGICA, 2013, 126 (05) : 671 - 682
  • [32] Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease
    Shi, Min
    Tang, Lu
    Toledo, Jon B.
    Ginghina, Carmen
    Wang, Hua
    Aro, Patrick
    Jensen, Poul H.
    Weintraub, Daniel
    Chen-Plotkin, Alice S.
    Irwin, David J.
    Grossman, Murray
    McCluskey, Leo
    Elman, Lauren B.
    Wolk, David A.
    Lee, Edward B.
    Shaw, Leslie M.
    Trojanowski, John Q.
    Zhang, Jing
    ALZHEIMERS & DEMENTIA, 2018, 14 (08) : 1052 - 1062
  • [33] Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis
    Bjerke, Maria
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (03) : 1199 - 1209
  • [34] Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers
    Bridel, Claire
    Somers, Charisse
    Sieben, Anne
    Rozemuller, Annemieke
    Niemantsverdriet, Ellis
    Struyfs, Hanne
    Vermeiren, Yannick
    Van Broeckhoven, Christine
    De Deyn, Peter P.
    Bjerke, Maria
    Nagels, Guy
    Teunissen, Charlotte E.
    Engelborghs, Sebastiaan
    BRAIN, 2022, 145 (11) : 4056 - 4064
  • [35] Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Mattsson, Niklas
    Andreasson, Ulf
    Carrillo, Maria C.
    Persson, Staffan
    Shaw, Leslie M.
    Zegers, Ingrid
    Zetterberg, Henrik
    Blennow, Kaj
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 401 - 407
  • [36] Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer's disease
    Zhang, Liding
    Liang, Xiaohan
    Zhang, Zhihong
    Luo, Haiming
    JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES, 2022, 15 (01)
  • [37] Cerebrospinal fluid markers for prediction of Alzheimer's disease
    Zetterberg, H
    Wahlund, LO
    Blennow, K
    NEUROSCIENCE LETTERS, 2003, 352 (01) : 67 - 69
  • [38] Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease
    Lijun Wang
    Aging Clinical and Experimental Research, 2019, 31 : 185 - 191
  • [39] Microglial cerebrospinal fluid antibodies - Significance for Alzheimer disease
    McRae, A
    Ling, EA
    Wigander, A
    Dahlstrom, A
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 28 (1-3) : 89 - 95
  • [40] Tau oligomers in cerebrospinal fluid in Alzheimer's disease
    Sengupta, Urmi
    Portelius, Erik
    Hansson, Oskar
    Farmer, Kathleen
    Castillo-Carranza, Diana
    Woltjer, Randall
    Zetterberg, Henrik
    Galasko, Douglas
    Blennow, Kaj
    Kayed, Rakez
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (04): : 226 - 235